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Abstract
The aim of the present study was to evaluate the efficacy of re-irradiation (re-RT) in patients with advanced local relapses of glial
tumours and to define the factors influencing the result of the hyper-fractionated external beam therapy on progression after
primary management. We have analysed the data of 55 patients with brain tumours (GBM: 28) on progression, who were re-
irradiated between January 2007 and December 2018. The mean volume of the recurrent tumour was 118 cm3, and the mean
planning target volume (PTV) was 316 cm3, to which 32 Gy was delivered in 20 fractions at least 7.7 months after the first
radiotherapy, using 3D conformal radiotherapy (CRT) or intensity modulated radiotherapy (IMRT). The median overall survival
(mOS) from the re-RT was 8.4 months, and the 6-month and the 12-month OS rate was 64% and 31%, respectively. The most
important factors by univariate analysis, which significantly improved the outcome of re-RT were the longer time interval
between the diagnosis and second radiotherapy (p = 0.029), the lower histology grade (p = 0.034), volume of the recurrent tumour
(p = 0.006) and Karnofsky performance status (KPS) (p = 0.009) at the re-irradiation. Our low fraction size re-irradiation ≥ 8
months after the first radiotherapy proved to be safe and beneficial for patients with large volume recurrent glial tumours.
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1. Introduction
Gliomas, with incidence of 5/100 000 in adults, are the most
common primary central nervous system malignancies, peaking
between the fifth and sixth decades of life [1]. After initial mul-
timodal treatment, at least 70% recurrence rate of gliomas can be
expected [2–4]. By surgical therapy alone, the disease has a very
poor prognosis (median survival 4–6 months [5], whereas sur-
gery accompanied by radiotherapy (RT) ameliorates the median
survival data to 8–9 months. Together with concomitant and
sequential TMZ, better median survival values can be expected,
such as 15 months for glioblastomas, or even 2–5 years for
anaplastic gliomas [6].
In the case of recurrence with its considerable limitations,
and only if it is possible, surgical treatment has the highest
efficacy [7]. In certain good performance status patients with
good anatomical access to tumours, surgery is applicable, but
the resection outcome could be definitely limited by consid-
erable infiltration of nervous tissue and by higher morbidity
risk [8, 9]. As for other low grade and grade 3 cases,
temozolamide (TMZ) is the treatment of choice, if it was not
administered during the initial management. Thereafter and
for GBM second-line systemic treatment (such as chemo- or
biological therapy) and re-irradiation is optional, in the lack of
standardised treatment for recurrent gliomas [10]. Recently,
Tumour Treating Field (TTF), a novel therapeutic option
emerged prolonging the survival with further 6 months [1].
For systemic treatment, monoclonal antibody (bevacizumab),
chemotherapy (nitrosurea, lomustine, dose dense TMZ [9],
immune checkpoint blockade (nivolumab, pembrolizumab)
[11], or even vaccines (DCVax) [12–14] are options to con-
sider. For recurrent tumours, salvage re-irradiation could be
selected. The typical re-irradiation techniques and strategies
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for recurrent gliomas are conventionally fractionated RT,
brachytherapy, hypofractionated stereotactic radiosurgery
(FSRT), stereotactic radiosurgery (SRS) alone, or combina-
tion treatment with RT and systemic therapy, and palliative
RT [15, 16].
On reviewing several clinical trials, the 6- and 12-month
overall survival (OS-6 and OS-12), calculated from the time of
re-irradiation, were 73% and 36%, respectively, whereas the
6- and 12-month of progression free survival (PFS-6 and PFS-
12) were 43% and 17%, respectively [17]. Median OS (mOS)
was 7.4–12.7 months in other studies [18–22].
2. Materials and Methods
Between 2007 and 2018, at the Department of Oncotherapy,
altogether 55 patients with recurrent glial tumours were sub-
jected to re-irradiation. The present study has been carried out
in accordance with The Code of Ethics of the World Medical
Association (Declaration of Helsinki) for experiments involv-
ing humans. Informed consent was obtained from the patients
at their first clinical admission for the anonymised use of their
patient data for research purposes. According to Sect. 20/Q of
No. 23/2002 Decree of the Ministry of Health, Hungary, the
present study is considered as a non-interventional clinical
study. The whole present study was carried out according to
the ethical permission No. 4209/2018-SZTE, issued by the
Ethical Committee of our University. The treatment schemes
were thoroughly discussed with every single patient, indepen-
dently from their actual performance status. The re-irradiation
was agreed by signed informed consent. The initial care
consisted of surgery in each case. The patients with grade 2
and grade 3 brain tumours received radiotherapy only postop-
eratively and for GBM we applied adjuvant chemoradiation
therapy followed by temozolamide monotherapy up to pro-
gression. Magnetic resonance imaging (MRI) were performed
three monthly. Disease progression was defined by two inde-
pendent experts. At the time of diagnosis, the tumour grading
was based on histological assessment. At the time of re-RT,
histological evaluation was performed only in the re-operated
cases, in the case of the remaining patients (without re-opera-
tion), the grading was based on clinical and radiological eval-
uation. The re-irradiation volume was defined on the basis of
planning CT (computed tomography) and MRI fusion.
Patients were immobilised with a 3-point thermoplastic mask
(ORFIT Industries, NL). The planning target volume
encompassed the GTV (gross tumour volume) plus 0.3-1 cm
margin. The shapes of the recurrent tumours were frequently
highly irregular, sometimes with multiple manifestations, and
with spread to the contralateral hemisphere through the corpus
callosum; or spreading along the wall of the previous surgical
cavity and/or ventricle wall, resulting in larger PTV (planning
target volume). The normal structures were contoured
including the lens, optic chiasm, optic nerve, brain, and
brainstem. Treatment planning was performed with Eclipse
(version 5, Varian Medical Systems, Palo Alto, USA). The
re-RT dose was 32 Gy in 1.6 Gy daily fractions in all cases,
in order to avoid serious neurotoxicity. Dependent on the lo-
cation and extent of the recurrent glioma, 3 DCRT or IMRT or
VMAT (Rapid Arch) therapy-plans (VMAT) were generated
according to the ICRU (International Commission on
Radiation Units & Measurements, Inc.) 52 recommendation.
[23].
During brain irradiation, patients received 12 mg methyl-
prednisolone for prevention of brain oedema, with gradually
decreased dosing after radiotherapy. The dose of methyl-
prednisolone was adjusted according to the symptoms of in-
tracranial pressure elevation due to brain oedema. The major-
ity of the patients (32 over 23) received bevacizumab therapy
after the re-RT, and these patients were controlled in a bi-
weekly fashion, with physical examination up to progression
and 3-months intervals MRIs were performed, whereas for the
remaining group without bevacizumab treatment after re-RT,
the check-ups were scheduled in 4–6 weeks. Two experts
evaluated the images according to the RANO HGG
(Response Assessment in Neuro-Oncology High-grade glio-
ma) criteria [24]. We included all patients with a recurrent
glial tumour who completed the 32 Gy re-irradiation in 20
fractions to the present analysis. We assessed retrospectively
the overall survival (OS) from the diagnosis, and from the first
day of the re-irradiation according to the, age, Karnofsky per-
formance score (KPS), primary tumour grade and histopathol-
ogy type, the type of the primary tumour removal, size of
GTV, size of PTV, time interval between two irradiations,
time elapsed between diagnosis and 2nd RT, second line
bevacizumab treatment. The data were evaluated by Kaplan-
Meier statistical analysis with IBM SPSS Statistics for
Windows, Version 20.0 (Armonk, NY: IBM Corp.) p value
< 0.05 was considered as statistically significant. COX regres-
sion was used for univariate, as well as multivariate analysis.
Factors with significance in univariate analysis were included
into a multivariate analysis. After the re-irradiation we record-
ed the KPS, Mini Mental Score (MMS) and daily activity in
every visit.
3. Results
3.1 Patient Characteristics
Table 1 summarises the patient characteristics. The mean age
of the population at the time of the primary diagnosis detection
was 39 years (range: 11–71 years); 49% of themwas male and
51% female. Themean age at the time of the re-irradiationwas
42 years (range: 13–72 years). The KPS was in 40% of this
population over 70%. At the beginning of the reirradiation,
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majority of the patients had minor neurological symptoms,
such as hemiparesis, facial paresis, focal seizure partly con-
trolled by antiepileptic medication, more frequently motor and
sensory aphasia. Besides these symptoms, the patients pre-
served the ability of self-caring, except 5 patients with serious
paresis needing regular help in their daily life. Out of 23 cases
with repeated surgery, only four initially grade 2–3 tumours
showed malignant transformation to grade 3–4. In the major-
ity of the cases, though, reoperation took place relatively early
during the course of the disease. Usually in the case of initially
low grade tumours, surgery was performed prior to the first
oncological management; and also grade 3 tumours were as
well as re-operated some years prior to reirradiation. In 84% of
the cases, based on the clinical behaviour of the tumour, their
malignant transformation was highly probable at the time of
reirradiation, but no regular biopsy was performed in order to
confirm it. The average time interval between the diagnosis
and re-irradiation was 47.4 months (range: 7.3–228 months)
first and the re-irradiation was 36 months (range: 7.7–
232 months) respectively. All patients received first-line sys-
temic temozolomide treatment, either as part of initial postop-
erative management (GBM), or at the first relapse. 23 patients
were treated with bevacizumab monotherapy, as second-line
treatment. The re-irradiation was performed after the first-line
systemic treatment in 45 cases, and after second-line therapy
in 10 cases. The primary histological type was grade 2 astro-
cytoma in 15 cases, grade 3 glial tumour (anaplastic astrocy-
toma or oligodendroglioma) in 12 cases, and glioblastoma
mul t i f o rme (GBM) in 28 case s . MGMT (O-6 -
methylguanine-DNA methyltransferase) methylation status
was known in 26 cases. 16 patients were methylated, 9 pa-
tients borderline methylated and in one case MGMTwas non-
methylated.
3.2 Survival Analysis
Median survival was altogether 42.6 months, as calculated
from the date of the first diagnosis. The Table 2 shows the
survival data. Regarding histology, cases with lower, grade 2
malignancies had the most favourable survival values (111.0
months), whereas this value was 23 months (p < 0.001) in
cases with GBM.We found a strong correlation to histological
type: grade 2 astrocytoma cases had the longest survival
(114.8 months), whereas the worst survival was detected of
grade 4 cases (30.7 months; p ≤ 0.001).
The most important factors significantly influencing the
outcome of re-RT were the time interval between the first
and second radiotherapy, histology grade, GTV, and KPS at
the re-irradiation.
3.3 Survival from the Beginning of Re-irradiation
The mOS from the re-RT of the entire cohort was 8.4 months;
6 patients survived more than 10 months and 2 patients more
than 2 years. The 6-month and the 12-month OS rate was 64%
and 31% respectively.
The mean volume of GTV, as contoured during Re-RT,
was 118.0 cm3 (range: 4.5–304 cm3). Patients with lesser than
average GTV at re-RT had 12.9 months, patients with greater
than average GTV at re-RT had 5.5 month of median survival
(p = 0.006) (Fig. 1).
Patients with KPS > 70% at the beginning of re-RT had
significantly better survival values (10.4 months, p = 0.009),
than those ones with poorer general conditions (5.6 months)
(Fig. 2).
Comparing time interval (between diagnosis and second
radiotherapy, reRT) with OS on univariate analysis, patients
with an interval of more than 47 months from 1st to the 2nd
course of RT (mOS 10.2 vs. 6.7 months, hazard ratio (HR)
0.99, 95% confidence interval (CI) p = 0.029. (Fig. 3).
Median survival, as calculated from re-irradiation for the
entire group was 9.0 months. According to histopathology
GBM: 6.0 months, grade 2 + 3 malignancies 10.0 months;
p = 0.031.
These factors proved to be significant for OS from re-RT in
cox-regression univariate analysis. In multivariate analysis,
the smaller GTV and better KPS remained significant
influencing factors.
In the present study, no significant interrelation was found
between OS and age at re-RT, size of PTV, type of primary
surgical intervention, or whether the second-line bevacizumab
therapy preceded or followed the re-irradiation.
Table 1 Summary of the patient characteristics
Variables No. of the patients
Number of the patients 55
Sex
Male 27
Female 28
KPS
>70% 22
≤ 70% 33
Primary histopathology type
astrocytoma grade 2 15
oligodendroglioma grade 3 6
anaplastic astrocytoma grade 3 6
glioblastoma multiforme 28
Salvage surgery 23
Prior temozolomid treatment 55
MGMT methylation status
methylated 18
unmethylated 9
unknown 28
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3.4 Outcome and Toxicity of the Treatment
Due to the second radiotherapy at progression, amelioration of
neurological signs and KPS were experienced in 58% of our
patients. Control radiological imaging detected stable disease
or partial remission in 44 cases.
In the majority of the cases, the prophylactic dose and
escalated dose on demand of the methyl-prednisolone
prevented the development of serious brain oedema and the
consequent intracranial pressure elevation.We did not see any
radiation necrosis on the follow up MRIs and no major cog-
nitive deficit was associated to the re-RT assessed with MMS.
4. Discussion
In the past, re-irradiation for recurrent malignant gliomas was
considered with great reluctance due to the high risk of radi-
ation necrosis. In the recent decades after implementation of
advanced RT techniques, several retrospective analyses, re-
views, as well a prospective study and meta-analysis were
published proving that re-irradiation is useful treatment option
for recurrent brain tumours [16, 17, 25, 26].
The present work represents the establishment of a careful,
consequent re-RT approach with low fraction size to avoid
radiation sequelae using standardised target volume and dose
definition even for large volume recurrences. Selected studies
on SRS for small volume recurrences of median 6.2 to
28.0 cm3 [27–29] showed an improvement on median surviv-
al ranging from 5.3 to 13.0 months with associated
radionecrosis of 0–31.3%. Others have reported their results
for recurrent GBM volumes of median 7–50 cm3 applying
FSRT resulted in median survival within the range of 6.5–11
months [26, 30–32]. In contrast to these small target volumes
for re-RT with SRS techniques, lower doses to larger volumes
could be applied safely with acceptable efficacy, which was
confirmed by the first meta-analysis on re-irradiation pub-
lished by Kazmi et al. [17]. However, highly divergent
Table 2 Survival data. Significant correlations between investigated factors are highlighted with bold characters
Variable n OS (months) ± SE p-value
from initial diagnosis
Entire group 55 42.6 2.6
initial histopathology type
grade 2 15 114.8 40.2 p < 0.001
grade 3 12 52.2 9.8
grade 4 28 30.7 1.3
from re-RT
entire group 55 8.37 1.9
histopathology type at re-irradiation
grade2 (n = 12) + grade3 (n = 14) 26 10 1.2 p = 0.031
grade 4 29 6 2
GTV re-RT mean 118 cm3
≤ mean 29 12.9 3.9 p = 0.006
> mean 23 5.5 0.3
KPS at re-RT
≤70% 33 5.6 0.7 p = 0.009
>70% 22 10.4 1.9
Time between diagnosis (DG) and re-RT
≤47 months 18 6.7 p = 0.029
>47 months 37 10.2
PTV re-RT 316 cm3
≤ mean 33 10.1 1.5 p = 0.246
> mean 22 5.5 0.4
Age at re-irradiation
≤40 year 27 8.3 2.2 p = 0.704
>40 year 28 6.6 2.7
bevacizumab therapy before re-RT
no 32 6.5 1.1 p = 0.35
yes 23 10.2 0.3
2654 Dobi et al.
fractionation schemes and target volume concepts are applied
with heterogeneous median survival times between 5 and 18
months. Krauze et al. reported a mOS of 6 months after re-
irradiation of recurrent glioma with median 30 Gy [33].
Another recent study revealed that OS after salvage SRS or
hypofractionated RT (HFRT) does not significantly (p = 0.06)
differs from that after conventionally fractionated re-RT, and
the trend towards better OS probably related to smaller target
volume [34]. Analysis in a retrospective review has not shown
any differences in OS after stereotactic or conventionally frac-
tionated re-RT [35]. The similar outcome (mOS of 9.7
months) using conventional-, hypofractionated or SRS tech-
niques was confirmed by another retrospective analysis of re-
RT for recurrent malignant glioma [36]. The 9-month mOS
with re-RT achieved in our patients with GTV median of
118 cm3 falls within the range of previously reported series
KPS ≤ 70%
KPS > 70%
Overall survival (months)
lavivrus
evitalu
muC
p = 0.009
Fig. 2 Kaplan-Meier plot of the correlation between KPS and OS (p=0.009)
Overall survival (months)
GTV > 118 cm3
GTV ≤ 118 cm3
lavivrus
evitalu
muC
p = 0.006
Fig. 1 Kaplan-Meier plot of the correlation between GTV-re-irradiation and OS (p=0.006)
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[17, 25, 32]. There are only very few prospective reports on
the efficacy of re-RT. Shi and colleagues recently published
the late results from RTOG 0525 trial [37]. Patients received
BSC only had anmOS of 4.8 months versus the groups treated
with re-RT only, chemotherapy only or radiochemotherapy,
8.2, 10.5, 11.3 months, respectively [37]. It should be noted
that in this study OS was calculated from the first progression
and not from the beginning of re-RT, as it is in our present
study.Well-defined prognostic factors are established for glial
tumours; however, the factors influencing the outcome of re-
RT are less known. Different factors are considered to influ-
ence the efficacy of the survival after re-RT, such as age,
performance status, histological grading and the length of
the interval between the 1st and the 2nd course of RT [38,
39]. A recent meta-analysis and appraisal summarizes the ra-
diation parameters and outcomes of fractionated re-RT from
studies published from 1999 to 2018 [17, 40]. The re-RT was
delivered at a median time interval of 12 months (range: 3.5 to
19 months) with dose of 24 to 36 Gy with a daily fractional
size of 1.8 to 6 Gy. In our case, > 7 months passed after the 1st
RT and we applied 1.6 Gy fraction size. The 8.4 months OS of
our group is comparable to previous studies, reporting the
mOS from re-RT 7.5 to 11 months.
The evaluation of the clinical data in different series of re-
RT revealed important factors, which may improve the sur-
vival, such as KPS > 70%, age < 50 years, interval >
12 months between the first RT and re-RT, target volume <
20–30 cm3, radiation dose > 30–35 Gy.
In our study, significant predictors for a longer survival
after re-RT were the better performance status at re-RT, the
longer interval from 1st line treatment to re-RT and lower
tumour grade both at diagnosis and at re-RT. The age at re-
RT proved not to be a prognostic factor, however, the mean
age was below 40 years. The tumour size (i.e. GTV) was one
of the most significant factors for the prognosis of our patients,
whilst the PTV exhibited no significant relationship to the OS.
Recurrent tumour volume remained the strongest factor in
multivariate analysis (p = 0.038). The importance of the
interval-factor is in line with former reports of re-RT. It can
be assumed that the time of the first relapses after the primary
treatment is an indicator of the biological behaviour of the
tumour [25, 38, 39]. In our patient group, the median survival
according to the histopathological grade was higher than in
other reported studies (the median survival is around 55–
60 months for grade 2 and 18–26 months for grade 3 tu-
mours). [41]. It could be explained with the natural patient
selection and the younger age (inclusion of paediatric
patients).
In our cases, re-challenge of temosolomide was never ap-
plied, hence the primary monotherapy part was not limited in
time, it was administered up to progression. Therefore, the
MGMT promoter hypermethylation had less importance, be-
cause the re-irradiation was delivered when all patients devel-
oped resistance to TMZ. The MGMT status defined at the
initial diagnosis was available for 27 cases, obviously with
no significance on survival after re-RT. Other recent proven
biological factors, such as ATRX and IDH- mutation were
only partially available in our patient group.
Therefore this report is limited by the lack of detailed mo-
lecular analysis as well as by the retrospective methodology
p = 0.029
TimeDG-reRT > 47 months
TimeDG-reRT ≤ 47 months
Overall survival (months)
lavivrus
evitalu
muC
Fig. 3 Kaplan-Meier plot of the correlation between time (DG-reRT) and OS (DG=diagnosis; p=0.029)
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which could result in a selection bias as well as an
underreporting of low-grade toxicities. However, the selection
bias could be reduced by the homogenous treatment concept
for our cohort of patients. Nevertheless, comparison to BSC-
series remains to be difficult, and conclusions about survival
benefits due to intervention should be drawn with caution.
Furthermore, due to the still short survival after re-irradiation,
objective long-term responses after re-RT were not possible to
assess for all patients.
Due to the therapy, amelioration of neurological signs and
KPS were experienced in 58% of our patients. Control radio-
logical imaging detected stable disease or partial remission in
44 cases (78.6%).
Although standards of salvage therapy are not yet defined
for recurrent glial tumours, mainly due to paucity of high-
level prospective or randomized controlled studies, re-RT of
various technique is an established salvage option for selected
patients [42].
5. Conclusion
Smaller recurrent tumour size, better PS, longer interval from
1st line treatment to re-RT and lower tumour grade predict
better outcome from re-RT. No radiation-associated serious
adverse events were observed and the re-RT improved the
performance status and neurologic symptoms in the majority
of the cases. Re-irradiation with low fraction size in large
volume recurrent gliomas proved to be safe and seems to be
clinically beneficial in selected patient group.
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